MIRA Pharmaceuticals, Inc.
MIRAHealthcareNASDAQDrug Manufacturers - General
Scan Results
Daily timeframeMIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company carries a $35.7M market cap, placing it firmly in the micro-cap category. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a next-generation oral NMDA receptor modulator, that has completed a Phase 1 clinical trial.
Market Cap
$35.7M
Beta
1.55
P/E (TTM)
—
P/E (Fwd)
-2.07
EPS (TTM)
$-1.21
EPS (Fwd)
$-0.41
ROE
-217.1%
ROA
-129.6%
Cash
$8.1M
Total Debt
$0
Free CF
-$1.0M
52W Change
-38.1%
Annual Financials
Cash vs Debt
Where MIRA stands vs its 150-day and 200-day moving averages
As of the August 18, 2026 close, MIRA finished 24.76% below its 150-day moving average ($1.05) and 31.90% below its 200-day moving average ($1.16). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is MIRA overbought or oversold?
At the August 18, 2026 close, MIRA's RSI(14) was 45.2, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
MIRA Pharmaceuticals, Inc. reports $8.1M in cash and $0 in total debt. Free cash flow is running at -$1.0M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -217.1% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
A beta of 1.55 means MIRA is more volatile than average. Investors should be prepared for wider price swings relative to broader indices. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. No single metric tells the full story. Reviewing MIRA's risk profile alongside its fundamentals and technical indicators provides a more complete picture.